Abrocitinib Studied as Second-Line Biologic in Atopic Dermat

Abrocitinib shows consistent efficacy and safety in patients with moderate-to-severe atopic dermatitis, whether or not they've already been treated with a biologic, researchers report.

Related Keywords

Winston Salem , North Carolina , United States , Tennessee , Canada , Wake Forest University , Vanderbilt University , Lindsayc Strowd , Melinda Gooderham , Jamil Miller , Skin Centre For Dermatology , Vanderbilt University Medical Center , Drug Administration , Society For Investigative Dermatology , Investigative Dermatology , Bio Experienced With , Global Assessment , Eczema Area , Severity Index , Expand Treatment , Medscape Medical , Wake Forest University School , Dermatitis , Atopic Dermatitis , Jak Stat , Ak Stat Signaling Pathway , Ak Stat Cytokine Receptors , Biologic Therapy , Eczema , Riga ,